Committees

iPSC Joint Committee (JSRM-ISCT)

Aims & Scope

The objective of the committee is to drive the clinical translation of cell and gene therapies worldwide by engaging leaders and actors in the iPSC field to promote safe and effective iPSC-based therapies. The committee will seek to address some of the pre-clinical efficacy and safety issues at the core of iPSC translation, and provide a platform to discuss clinical testing, technologies, and the manufacturing of iPSC-based therapies.

  • Assist in the planning of the Annual Meeting scientific program and the review of submitted abstracts in the iPSC field
  • Review the status of the iPSC field and compile position papers on the relevant scientific issues that must be addressed to advance or enable cellular therapies utilizing iPSCs
  • Develop educational resources and engage in scientific discourse as necessary to advance the field

The iPSC Committee is jointly organized with the Japanese Society for Regenerative Medicine

The Committee

Headshot of Patrick Hanley

Co-Chair

Shin Kawamata, MD, PhD
November 2021 - Present

FBRI
Kobe, Japan

Headshot of Patrick Hanley

Co-Chair

Shin Kaneko, MD, PhD
November 2021 - Present

Kyoto University
Kyoto, Japan

MEMBERS

Ross Meyers, PhD
University of Wisconsin
Madison, United States

Shigeru Miyagawa, MD, PhD
Osaka University
Osaka, Japan

Yoji Sato, PhD
National Institute of Health Sciences
Kanagawa, Japan

Shigeto Shimmura, MD
Keio University
Tokyo, Japan

Jun Takahashi, MD, PhD
Kyoto University
Kyoto, Japan

Anthony Ting, PhD
Bone Therapeutics
Shaker Heights, United States

Marc Turner, MB, ChB, PhD, MBA, FRCP, FRCPath, FHEA
Scottish National Blood Transfusion Service
Edinburgh, United Kingdom

Dominic Wall, PhD, FFSc (RCPA)
Peter MacCallum Cancer Center
Melbourne, Australia